197094-19-2

Basic information

• Product Name: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one
• Synonyms: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one;6,7-dihydro-5H-pyrazolo[1,5-a]pyridin-4-one
• CAS NO: 197094-19-2
• Molecular Formula: C7H8N2O
• Molecular Weight: 136.15122
• Mol File: 197094-19-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 281.8±9.0 °C(Predicted)
• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.18±0.20(Predicted)
• CAS DataBase Reference: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one(197094-19-2)
• EPA Substance Registry System: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one(197094-19-2)

Safety Data

• Hazardous Substances Data: 197094-19-2(Hazardous Substances Data)

Usage

General Description

6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one is a chemical compound that belongs to the pyrazole and pyridine groups. It is a heterocyclic compound with a cyclic structure containing two nitrogen atoms. 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one has been studied for its potential pharmaceutical properties, particularly as an anti-inflammatory and analgesic agent. It may also have applications in the field of medicinal chemistry for the development of new drugs. The chemical structure and properties of 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one make it a subject of interest for further research and potential therapeutic applications.

Upstream product

• 110525-56-9 4-(1H-pyrazol-1-yl)butanoic acid 
• 110525-55-8 4-Pyrazol-1-yl-butyric acid ethyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors

We report herein the synthesis of novel ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors and the evaluation of pharmaceutical activity against five cancer cell lines (MDA-MB-231, BXPC-3, NCI-H1975, DU145 and 786O). Generally, the majority of compounds displayed strong anti-FAK enzymatic potencies (IC50 1 nM) and could effectively inhibit several class of cancer cell lines within the concentration of 3 μM in comparison with GSK2256098 as a reference. Among them, compound 4o is considered to be the most effective due to high sensitivity in antiproliferation. In culture, 4o could not only inhibit FAK Y397 phosphorylation in MDA-MB-231 cell line, but also trigger apoptosis in a dose-dependent manner. Furthermore, computational docking analysis also suggested that 4o and TAE-226 displayed the similar interaction with FAK kinase domain.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Novel Parham-type Cycloacylations of 1H-Pyrazole-1-alkanoic Acids

Exposure of 1H-pyrazole-1-alkanoic acids to two equivalents of n-butyllithium affords the corresponding cyclic ketones via a Parham-type cyclization process. Although yields are modest, this procedure represents a simple and direct intramolecular acylation of a non-nucleophilic pyrazole carbon.